Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF

被引:136
|
作者
Emuss, V
Garnett, M
Mason, C
Marais, R
机构
[1] Inst Canc Res, Signal Transduct Team, Canc Res UK, Ctr Cell & Mol Biol, London SW3 6JB, England
[2] Wellcome Trust Sanger Inst, Hinxton, England
基金
英国惠康基金;
关键词
D O I
10.1158/0008-5472.CAN-05-1683
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The protein kinase B-RAF is mutated in similar to 8% of human cancers. Here we show that presumptive mutants of the closely related kinase, C-RAF, were detected in only 4 of 545 (0.7%) cancer cell lines. The activity of two of the mutated proteins is not significantly different from that of wild-type C-RAF and these variants may represent rare human polymorphisms. The basal and B-RAF-stimulated kinase activities of a third variant are unaltered but its activation by RAS is significantly reduced, suggesting that it may act in a dominant-negative manner to modulate pathway signaling. The fourth variant has elevated basal kinase activity and is hypersensitive to activation by RAS but does not transform mammalian cells. Furthermore, when we introduce the equivalent of the most common cancer mutation in B-RAF (V600E) into C-RAF, it only has a weak effect on kinase activity and does not convert C-RAF into an oncogene. This lack of activation occurs because C-RAF lacks a constitutive charge within a motif in the kinase domain called the N-region. This fundamental difference in RAF isoform regulation explains why B-RAF is frequently mutated in cancer whereas C-RAF mutations are rare.
引用
收藏
页码:9719 / 9726
页数:8
相关论文
共 50 条
  • [31] Exploiting c-RAF dependency in RAS mutant cancer: beyond catalytic activity
    Cooke, Sean F.
    Blair, Connor M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (3-4) : 95 - 100
  • [32] B- and C-RAF display essential differences in their binding to Ras - The isotype-specific N terminus of B-RAF facilitates ras binding
    Fischer, Andreas
    Hekman, Mirko
    Kuhlmann, Juergen
    Rubio, Ignacio
    Wiese, Stefan
    Rapp, Ulf R.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (36) : 26503 - 26516
  • [33] Differential temporal regulation of the MAPK1,2 network by MSH and FGF determined by signal integration at B-Raf and C-Raf in melanoma
    Muller, Melissa
    Ram, Prahlad T.
    CANCER RESEARCH, 2006, 66 (08)
  • [34] TRIBUTYLTIN CAUSES ACTIVATION OF C-RAF IN HUMAN NATURAL KILLER CELLS
    Celada, Lindsay J.
    Whalen, Margaret
    FASEB JOURNAL, 2009, 23
  • [35] c-Raf kinase binds to N-terminal domain of c-Myc
    Alexandrov, I
    Shlyakhova, L
    Vartanian, A
    Zajac-Kaye, M
    Alexandrova, N
    FEBS LETTERS, 1997, 414 (02): : 465 - 470
  • [36] c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
    Blasco, Rafael B.
    Francoz, Sarah
    Santamaria, David
    Canamero, Marta
    Dubus, Pierre
    Charron, Jean
    Baccarini, Manuela
    Barbacid, Mariano
    CANCER CELL, 2011, 19 (05) : 652 - 663
  • [37] Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations
    A Zebisch
    M Haller
    K Hiden
    T Goebel
    G Hoefler
    J Troppmair
    H Sill
    Leukemia, 2009, 23 : 1049 - 1053
  • [38] Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations
    Zebisch, A.
    Haller, M.
    Hiden, K.
    Goebel, T.
    Hoefler, G.
    Troppmair, J.
    Sill, H.
    LEUKEMIA, 2009, 23 (06) : 1049 - 1053
  • [39] Raf-1 and B-Raf promote protein kinase C θ interaction with BAD
    Hindley, Alison
    Kolch, Walter
    CELLULAR SIGNALLING, 2007, 19 (03) : 547 - 555
  • [40] Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations
    Haller, M.
    Zebisch, A.
    Hiden, K.
    Hoefler, G.
    Sill, H.
    Troppmair, J.
    FEBS JOURNAL, 2010, 277 : 127 - 127